Financials

v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2016
Sep. 30, 2015
Current Assets:    
Cash $ 126,578 $ 43,635
Accounts receivable 86,533
Prepaid expenses 42
Total current assets 213,111 43,677
Non-current Assets    
Intellectual property, net 5,609,501 1,651,875
Website development cost, net 19,125
Patent costs, net 126,476 143,178
Total non-current assets 5,755,102 1,795,053
Total Assets 5,968,213 1,838,730
Current Liabilities:    
Accounts payable 420,666 159,598
Accrued expenses 571,784 320,000
Accrued expenses due to related party 176,892 141,717
Convertible notes payable, net of unamortized discount of $8,556 103,944
Convertible notes payable to related party, net of unamortized discount of $31,138 468,862
Derivative liability 235,709
Total current liabilities 1,977,857 621,315
Total Liabilities 1,977,857 621,315
Commitments and Contingencies
Stockholders' Equity    
Common Stock ($0.00001 par value), 450,000,000 shares authorized; 217,254,543 and 95,944,743 shares issued; 215,479,543 and 95,162,243 shares outstanding as of June 30, 2016 and September 30, 2015, respectively 2,173 959
Additional paid-in capital 25,121,536 11,030,534
Accumulated deficit (21,133,353) (9,814,078)
Total Stockholders' Equity 3,990,356 1,217,415
Total Liabilities and Stockholders' Equity 5,968,213 1,838,730
Series B preferred stock    
Stockholders' Equity    
Preferred stock, $0.001 par value; 50,000,000 shares authorized

Source

v3.7.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]        
Revenue $ 91,533 $ 91,533
Cost of revenue 52,762 52,762
Gross profit 38,771 38,771
Operating expenses:        
Selling, general and administrative 475,426 100,597 780,739 379,899
Research and development 25,000 25,000
Research and development - license acquired 10,080,000 10,080,000
Professional fees 97,931 51,842 216,181 112,600
Merger costs     641,126
Total operating expenses 10,653,357 177,439 11,076,920 1,158,625
Loss from operations (10,614,586) (177,439) (11,038,149) (1,158,625)
Other expense        
Interest expense (36,131) (49,977)
Loss on change in fair value of derivative (236,270) (231,149)
Total other expense (272,401) (281,126)
Net Loss $ (10,886,987) $ (177,439) $ (11,319,275) $ (1,158,625)
Loss per Share:        
Basic and diluted net loss per common share outstanding $ (0.07) $ 0.00 $ (0.09) $ (0.01)
Basic and diluted weighted average number of common shares outstanding 167,095,654 94,384,418 120,526,942 82,848,540
Comprehensive loss:        
Net loss $ (10,886,987) $ (177,439) $ (11,319,275) $ (1,158,625)
Unrealized loss on available for sale securities (900,000) (1,600,000)
Comprehensive loss $ (10,886,987) $ (1,077,439) $ (11,319,275) $ (2,758,625)

Source

v3.7.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash Flows from Operating Activities:    
Net loss $ (11,319,275) $ (1,158,625)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 194,812
Amortization of debt discounts 29,755
Merger costs 641,126
Research and development - license acquired 10,080,000
Stock-based compensation expenses 71,252 388
Common stock issued for services 58,885
Loss on change in fair value of derivatives 231,149
Changes in operating assets and liabilities:    
Accounts receivable 19,101
Prepaid expenses 42 (30)
Accounts payable 54,609 (48,685)
Accrued expenses - related party (72,075) 318,457
Accrued liabilities 280,229 33,853
Net cash used in operating activities (430,401) (154,631)
Cash Flows from Investing Activities:    
Cash acquired with acquisition of Theranostics Health, Inc. assets 37,518
Licensing costs (12,924) (59,378)
Website development costs (21,250)
Net cash provided by (used in) investing activities 3,344 (59,378)
Cash Flows from Financing Activities:    
Proceeds from sale of common stock ,net 310,000 340,000
Proceeds from warrant and option exercises 1,300
Proceeds from convertible notes payable 100,000
Proceeds from convertible notes payable, related party 100,000
Net cash provided by financing activities 510,000 341,300
Net increase in cash 82,943 127,291
Cash at beginning of period 43,635 6,000
Cash at end of period 126,578 133,291
Supplemental disclosure of noncash investing and financing activities:    
Net liabilities assumed in connection with recapitalization 70,000
Effect of recapitalization 71,384
Shares issued in settlement of related party debt 428,575
Reclass derivative liability to equity upon note payment 52,389
Common stock issued to acquire net assets of Theranostics Health, Inc. $ 3,150,000

Source